2 citations
,
December 2013 in “Cancer research” In this study, GTx-027, a selective androgen receptor modulator, significantly inhibited tumor growth in certain breast cancer models and showed good tolerance in a Phase II trial with postmenopausal women.
68 citations
,
April 2014 in “Journal of Molecular Endocrinology” This review summarizes existing knowledge on androgen receptor activity in breast cancer and reports no new clinical findings, with emphasis on therapies targeting androgen signaling in specific BC subtypes.
56 citations
,
July 2014 in “PloS one” This study found that selective androgen receptor modulators (SARMs) significantly inhibited tumor growth and metastasis-promoting factors in AR-positive triple-negative breast cancer models.
1 citations
,
September 2020 in “Endocrinology, Diabetes & Metabolism Case Reports” This case report describes a woman with hypertension, alopecia, and other symptoms, revealing that her condition was due to ovarian hyperthecosis, highlighting the overlap of adrenal and ovarian disorders.
21 citations
,
March 2019 in “Critical Reviews in Clinical Laboratory Sciences” This review discusses the role of the androgen receptor in breast cancer diagnosis and treatment, and notes a lack of new research results on its therapeutic potential.